Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.

Qin W, Yang J, Ni Y, Deng C, Ruan Q, Ruan J, Zhou P, Duan K

Endocrine8 Jun 2024Cited by 43 (Europe PMC)

PMID38850440PMCIDPMC11445313DOI10.1007/s12020-024-03896-zPepBankPUB-38850440

Summary

AimTirzepatide, a newly developed dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has received approval for treating type 2 diabetes (T2D) and is currently being studied for its potential in long-term weight control. We aim to explore the safety and efficacy of once-weekly subcutaneous tirzepatide for weight loss in T2D or obese patients.MethodsA comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D. The mean difference (MD) and risk ratio (RR) were calculated for continuous and dichotomous outcomes, respectively. The risk of bias was evaluated using the RoB-2 tool (Cochrane), while the statistical analysis was conducted utilizing RevMan 5.4.1 software.ResultsSeven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified. Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss. The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively. Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively. All three doses of tirzepatide also significantly reduced body mass index and waist circumference. Furthermore, it led to a greater percentage of patients experiencing weight loss exceeding 5, 10, 15, 20, and 25%. Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles. In terms of safety, gastrointestinal side effects were the most frequently reported adverse events in all three doses of tirzepatide groups, which were generally mild-to-moderate and transient.ConclusionTirzepatide treatment could lead to remarkable and sustained weight loss that is well-tolerated and safe, representing a novel and valuable therapeutic strategy for long-term weight management.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 5 mg reduced body weight percentage more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 5 mg led to more percentage weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent change in body weight, 5 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−8.07%
5 mg
Source sentences
Summary
The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss.
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044001
02HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 10 mg reduced body weight percentage more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 10 mg led to more percentage weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent change in body weight, 10 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−10.79%
10 mg
Source sentences
Summary
The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss.
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044002
03HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 15 mg reduced body weight percentage more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 15 mg led to more percentage weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreasePercent change in body weight, 15 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−11.83%
15 mg
Source sentences
Summary
The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss.
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044003
04HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 5 mg reduced absolute body weight more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 5 mg led to more kilograms of weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in body weight, 5 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−7.5 kg
5 mg
Source sentences
Summary
Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044004
05HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 10 mg reduced absolute body weight more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 10 mg led to more kilograms of weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in body weight, 10 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−11 kg
10 mg
Source sentences
Summary
Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044005
06HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide 15 mg reduced absolute body weight more than placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide 15 mg led to more kilograms of weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseAbsolute change in body weight, 15 mg
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Measurements
MD
−11.5 kg
15 mg
Source sentences
Summary
Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044006
07HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide at all three doses reduced body mass index versus placebo.
In plain wordsIn adults with obesity or type 2 diabetes, all three tirzepatide doses lowered BMI more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 and 15 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
All three doses of tirzepatide also significantly reduced body mass index
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044007
08HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide at all three doses reduced waist circumference versus placebo.
In plain wordsIn adults with obesity or type 2 diabetes, all three tirzepatide doses reduced waist size more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 and 15 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
All three doses of tirzepatide also significantly reduced body mass index and waist circumference.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044008
09HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, a greater proportion of patients on tirzepatide lost more than 5, 10, 15, 20 and 25% of body weight than on placebo.
In plain wordsIn adults with obesity or type 2 diabetes, more people lost large amounts of weight on tirzepatide than on placebo.
Peptide
Tirzepatide
Outcome
IncreaseProportion with weight loss above 5, 10, 15, 20 and 25%
Study
n = 4,795
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, it led to a greater percentage of patients experiencing weight loss exceeding 5, 10, 15, 20, and 25%.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044009
10HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide reduced blood pressure versus placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide lowered blood pressure compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseBlood pressure
Study
n = 4,795
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044010
11HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide reduced blood sugar levels versus placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide lowered blood sugar compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseBlood sugar levels
Study
n = 4,795
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044011
12HumanSystematic reviewEfficacy outcome
In adults with obesity or type 2 diabetes, tirzepatide improved lipid profiles versus placebo.
In plain wordsIn adults with obesity or type 2 diabetes, tirzepatide improved blood fat levels compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseLipid profiles
Study
n = 4,795
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044012
13HumanSystematic reviewSafety outcome
In adults with obesity or type 2 diabetes, gastrointestinal side effects were the most frequent adverse events at all tirzepatide doses, mostly mild to moderate and transient.
In plain wordsIn adults with obesity or type 2 diabetes, stomach and gut side effects were the most common with tirzepatide and were mostly mild and short.
Peptide
Tirzepatide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n = 4,795
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 and 15 mg · subcutaneous · 12 to 72 weeksAs given in this study (human).
Source sentences
Summary
In terms of safety, gastrointestinal side effects were the most frequently reported adverse events in all three doses of tirzepatide groups, which were generally mild-to-moderate and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D.
Summary · context
Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified.
Show in the study text Report a problemFND-3885044013

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.